Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer - Quiz - MDSpire

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • By

  • Yulu Wang

  • Chengyang Luo

  • Yueze Li

  • Jiayu Pei

  • Dian Wang

  • Pei Wang

  • Jing Li

  • June 12, 2026

  • 0 min

Share

Original Source(s)

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • by Yulu Wang, Chengyang Luo, Yueze Li, Jiayu Pei, Dian Wang, Pei Wang, Jing Li

  • June 12, 2026

Related Content

Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

I’ve spent 40 years in research. I have never seen a threat to science like the new grantmaking rule

The future of neurosurgical oncology lies in cognitive neurosciences: understanding brain processing is much more valuable than surgical technology